Nabta Health

Dubai, United Arab Emirates

Medical Devices Telehealth/Virtual Care Women's Health

Nabta Health is a hybrid healthcare platform for women, empowering the 500 million women in MEASA (Middle East, Africa, South Asia) to effectively manage their health. Nabta aims to make healthcare affordable and accessible to all women by seamlessly integrating virtual care components such as mobile apps, smart medical devices and tests, and virtual consultations, with traditional care. Today, the treatment of women's health issues is reactive, inconsistent and poor quality. Tests, drugs and invasive treatment methods are heavily over-prescribed, particularly in the GCC, with little or no consideration for the individual in question. Women can waste thousands of dollars and hundreds of hours pursuing diagnosis and treatment options that are inappropriate for them. Moreover, there is no way for women to identify correlations between their wellness, health and medical data, meaning they have no way to see (for example) how their sleep patterns may be affecting their stress levels, which could have a detrimental effect on their hormone levels and so affect everything from cycle regularity to blood sugar levels. Nabta's solution is a hybrid model of care that empowers women to manage their own health by connecting their wellness, health and medical data and drawing actionable insights from them.

✓Source: HealthTech Alpha by Galen Growth

Shareable draft

Check out Nabta Health on @MedStartr Today #WomenSHealth #MaternalHealth #MedicalDevices #TelehealthVirtualCare #MedMo #MedStartrVentures

https://www.medstartr.ai/s/Rgr7-kK80yw

Get Involved in Nabta Health

🏢Is this your company? Claim This Profile

Join MedStartr to verify with your work email and edit this profile

Company Info

Founded: 2018
Website: nabtahealth.com/

Disease Areas

Women's Health Maternal Health

Technologies

Mobile ApplicationsVirtual Care PlatformsDiagnostic Testing

🌐Website

MedStartr Engagement Score

The MedStartr Index is a reflection of how the crowds that come to MedStartr everyday to find healthcare innovations reacted. Calculated by our AI agent Fyggy based on algorithms we have been building since 2012 and over 100 different factors, the math is proprietary and complex. Suffice to say, it has been found to be highly correlative with early stage company growth. What you see here is the public version. To learn more or to get deeper access to our predictive data on startup success for your fund or company, click here.

Comments

Comments from new members are shown once the company's team has approved them. Please follow the community rules.

Be the first to comment.

What do you think of Nabta Health?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Clinical Benefit Potential

The potential for a project to have a large and significant impact on medical care, treatment, or prevention.

Feasibility

The likelihood that this will provide benefit for patients / care givers and that the founders can execute on their vision and plan.

Innovativeness

The distinguishing features, concept, or technology that differentiates the entry compared to others that already exist and are in widespread use.

Fundability

The reviewers' beliefs that the idea is fundable or can make it to sustainability without outside investment.

Scalability

Some great ideas are destined to failure because they are too complex or too expensive. The reviewer should consider the likelihood that a project as explained, or perhaps with some tweaks, could possibly become a worldwide solution within a reasonable time frame.

Presentation Quality

How well the team presented the idea.

Submit anonymously — my name won't be shown to the team or on this profile

Your scores and comments are shown with your review on this company's profile.